background prospective randomized pilot clinical study was conducted to evaluate the beneficial effects of inositol hexaphosphate ip6  inositol in breast cancer patients treated with adjuvant therapypatients and methods patients with invasive ductal breast cancer where polychemotherapy was indicated were monitored in the period from 20052007fourteen patients in the same stage of ductal invasive breast cancer were involved in the study divided in two randomized groupsone group was subjected to take ip6  inositol while the other group was taking placeboin both groups of patients the same laboratory parameters were monitoredwhen the treatment was finished all patients have filled questionnaires qlq c30 and qlqbr23 to determine the quality of liferesults patients receiving chemotherapy along with ip6  inositol did not have cytopenia drop in leukocyte and platelet countsred blood cell counts and tumor markers were unaltered in both groupshowever patients who took ip6  inositol had significantly better quality of life p  005 and functional status p  00003 and were able to perform their daily activitiesconclusion ip6  inositol as an adjunctive therapy is valuable help in ameliorating the side effects and preserving quality of life among the patients treated with chemotherapy